Gastrointestinal Cancer

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses treatment options for patients with neuroendocrine tumors (NETs).

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the FDA breakthrough designation status of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (CRC).

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the changing landscape of metastatic colorectal cancer (mCRC).

Afsaneh Barzi, MD, assistant professor of clinical medicine, USC Norris Comprehensive Cancer Center, discusses surgical advances in the treatment of patients with pancreatic cancer.

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses maintenance therapy for patients with metastatic colorectal cancer.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the potential of immunotherapy in the treatment landscape of hepatocellular carcinoma.

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.

Ghassan K. Abou-Alfa, MD, discusses the potential of the oncolytic virus Pexa-Vec and other developments in hepatocellular carcinoma.

Charles S. Fuchs, MD, MPH, has investigated associations between lifestyle choices of food and exercise and cancer diagnosis and survivorship, leading to important insights that have clarified the relative value of diets that include nuts, alcohol, and legumes, among other foods.

David J. Pinato, MD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses the role of PD-L1 testing in hepatocellular carcinoma.

Ann-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.

Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discussed second-line therapy for patients with hepatocellular carcinoma.

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.